STOCK TITAN

HeartSciences (HSCSW) SEC Filings

HSCSW NASDAQ
Rhea-AI Summary

HeartSciences Inc. (HSCS) reported vote totals from its November 19, 2026 special meeting, where 4,041,647 shares, or 76.36% of shares entitled to vote, were represented. The merger proposal received 3,480,989 votes for and 20,933 against; the related Nasdaq proposal received 3,459,400 for and 43,445 against.

The Nasdaq proposal sought approval for up to 35,000,000 additional Class A shares through specified private placements, conversions or exercises, or debt exchanges within one month of closing. Total aggregate consideration was capped at $100,000,000, and the applicable price, conversion rate, or exchange rate was subject to a maximum 20% discount to market price. The reverse-split proposal received 3,981,498 votes for and 40,735 against; it was subject to board discretion and mutual agreement with Fortitude Seller on a ratio from 1-for-2 to 1-for-5. Shareholders also voted on charter changes, including a proposed company name change to Fortitude Mining Group, Inc.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.54%
Tags
current report
-
Rhea-AI Summary

HeartSciences Inc. (HSCS) may offer common stock with an offering price of up to $3,077,649 through Maxim Group LLC under an at-the-market offering, subject to Form S-3's I.B.6 limit. Sales may occur from time to time at market prices; Maxim is not required to sell a set amount. The commission is 2.5% of gross sales while the limit applies and 2.0% thereafter. HeartSciences says it cannot assure it will receive proceeds.

The proposed merger with Fortitude is expected to close in the fourth quarter of 2026, subject to customary conditions including shareholder approval. Nasdaq accepted the company's compliance plan and set February 1, 2027 as the deadline to evidence compliance with its $2.5 million stockholders' equity minimum; HeartSciences reported $226,060 in stockholders' equity in its 2026 annual report. FDA clearance covers the MyoVista wavECG as a 12-lead resting ECG, not an AI algorithm; HeartSciences says it does not currently intend significant additional commercialization resources for that device. The company also disclosed substantial doubt about its ability to continue as a going concern and Fiscal 2026 material weaknesses in financial controls.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.54%
Tags
prospectus
-
Rhea-AI Summary

HeartSciences Inc. may offer common stock in an at-the-market offering for up to $3,077,649 in aggregate offering price under the current prospectus supplement. The Equity Distribution Agreement with Maxim Group LLC permits up to $50,000,000 in sales, included within the $200,000,000 base shelf. While the aggregate market value of the company’s voting and non-voting common shares held by non-affiliates is below $75 million, Form S-3 Instruction I.B.6 limits public primary sales to one-third of that value in any 12-month period.

After a placement notice, Maxim will use commercially reasonable efforts to sell shares under the company’s instructions and agreement conditions, but is not required to buy shares as principal. HeartSciences pays a 2.5% commission while subject to the Form S-3 limit and 2.0% thereafter, plus legal-fee reimbursement up to $15,000 for preparing and entering the agreement and up to $5,000 per Bringdown Date. Either party may terminate on notice; Maxim may also terminate in specified circumstances, including a material adverse change making marketing impractical or inadvisable.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.54%
Tags
current report
EFFECT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.54%
Tags
other
-
Rhea-AI Summary

HeartSciences Inc. filed a shelf prospectus covering up to $200,000,000 of common stock, preferred stock, debt securities, warrants, rights and units. Sales may occur only after the registration statement becomes effective and with a prospectus supplement; each offering’s amount and terms will be set in that supplement.

Until the earlier of the new registration statement’s effectiveness and March 27, 2027, HeartSciences may continue using its prior registration statement and supplements, including its at-the-market common-stock offering through or to Maxim as sales agent. The FDA cleared MyoVista wavECG on October 6, 2026 as a 12-lead resting electrocardiograph, but the clearance excludes an AI-ECG algorithm; commercializing the device with an impaired cardiac relaxation (e’) algorithm would require further development and separate FDA clearance. HeartSciences reported stockholders’ equity of $226,060 in its 2026 Annual Report, below Nasdaq’s $2,500,000 minimum. Nasdaq accepted its compliance plan, which identifies the proposed Fortitude merger, expected to close in Q4 2026, and gave the company until February 1, 2027 to evidence compliance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.54%
Tags
registration
-
Rhea-AI Summary

HeartSciences Inc. amended its merger-related report to add Fortitude Mining Holdings, Inc.’s unaudited interim financial statements and management discussion for the nine months ended September 30, 2026 and 2025. Fortitude’s mining revenues, net, were $57.9 million, compared with $59.9 million; its net loss was $16.247 million versus $15.582 million. Operating cash flow was $9.5 million, compared with $6.5 million.

Mining revenues, net, fell 3%: a $32.6 million increase in Zcash revenue was offset by declines in bitcoin and other digital-asset mining. Fortitude mined 90,582 Zcash and 226 bitcoin, down 51% each. EBITDA and Adjusted EBITDA, both non-GAAP measures, were a $3.024 million loss versus $4.156 million income and $17.069 million versus $6.919 million, respectively. The related-party DCG credit facility commitment rose to $70 million in October, with $27.6 million outstanding as of September 30, 2026. The merger is expected to close in the fourth quarter of 2026, subject to closing conditions including HeartSciences shareholder approval at the November 19, 2026 special meeting. At closing, DCG is expected to hold approximately 94% of the combined company’s voting interests on a fully diluted basis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.09%
Tags
current report
Rhea-AI Summary

HeartSciences Inc. added transaction-background and financial-advisor analysis to its proxy materials for the proposed merger in which Cordis Acquisition, LLC would merge into Fortitude Mining HoldCo, LLC, with Fortitude Mining HoldCo surviving. The added background says the January 6, 2026 letter of intent set a 60-day exclusivity period, subject to an automatic extension for an additional 15 days if the parties continued to negotiate in good faith. It also provided that Fortitude would select the combined company’s management and board, while the parties would discuss employment or retention agreements with certain HeartSciences managers.

Houlihan Capital’s guideline public-company analysis indicated Fortitude equity value of $206,001,900 to $428,189,900. The analysis used total debt of $0 and cash and cash equivalents of approximately $12.2 million as of May 31, 2026. The supplement states that the virtual special meeting remains scheduled for November 19, 2026, at 10:00 a.m. Eastern Time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.80%
Tags
current report
-
Rhea-AI Summary

HeartSciences Inc. is the issuer in a joint beneficial-ownership disclosure by North Rock Digital, LP, North Rock Digital GP, LLC, Positivo LLC, Positivo Management LLC, Philip H. Press and Alexander M. Wlezien. North Rock directly owns 176,461 shares (3.55%), while Positivo directly owns 122,810 shares (2.47%). North Rock GP and Positivo Management may be deemed to share voting and dispositive power over their respective entities’ shares.

Press and Wlezien may each be deemed to beneficially own an aggregate 299,271 shares (6.02%). They hold managing membership interests in North Rock GP and are members and Co-Chief Investment Officers of Positivo Management, with authority over investment and trading decisions. The percentages are based on 4,969,283 shares outstanding as of October 8, 2026. The reporting persons disclaim beneficial ownership except to the extent of their respective pecuniary interests, and the joint filing is not an admission that they formed a group.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.33%
Tags
ownership
-
Rhea-AI Summary

HeartSciences Inc. reports that Andrew Simpson, its President, Chief Executive Officer and Chairman, beneficially owns 403,739 shares, or 7.5% of the class. The reported amount includes 323,833 shares issuable upon exercise of options; all options fully vested as of October 5, 2026, following FDA 510(k) clearance of the MyoVista wavECG device. It also includes 70,000 voting restricted shares that vest upon closing the transactions contemplated by the merger agreement, and excludes 425,000 unvested, non-voting restricted shares.

Simpson states the securities were acquired for investment purposes. He may communicate with stockholders, officers, directors and others about HeartSciences’ operations and strategic direction, including discussions that could concern debt or equity financing, acquisitions, mergers or other strategic transactions; he reserves the right to revise his position and take future actions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
182.61%
Tags
ownership
Rhea-AI Summary

HeartSciences Inc. asks shareholders to approve its proposed combination with Fortitude Mining Holdings, Inc. (the Fortitude Seller), subject to closing conditions, at a November 19, 2026 meeting. HeartSciences would transfer substantially all its assets and liabilities to a subsidiary, which would merge into Fortitude HoldCo; Fortitude HoldCo would survive, with HeartSciences as sole managing member. The Fortitude Seller would exchange its voting units for Class V shares, carrying one vote each and no economic rights, and contribute $2,000,000 of cash or Zcash for Class A shares. The exchange ratio is 19.00, or 21.22 if the closing VWAP is equal to or greater than $7.50.

Under stated assumptions excluding potential PIPE and debt-exchange issuances, approximately 7,684,628 Class A and 107,407,836 Class V shares are expected outstanding after closing. The Fortitude Seller is expected to hold about 94% of voting interests; existing HeartSciences equityholders other than the seller, about 6% of voting and economic interests. Shareholders are also asked to approve potential Class A issuances of up to 35,000,000 shares within one month of Closing, with aggregate consideration of cash, Zcash or debt satisfaction capped at $100,000,000 and a maximum 20% discount to market price. A proposed one-for-two to one-for-five reverse split would have a ratio set by the board and mutually agreed with the Fortitude Seller.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.59%
Tags
proxy

FAQ

How many HeartSciences (HSCSW) SEC filings are available on StockTitan?

StockTitan tracks 61 SEC filings for HeartSciences (HSCSW), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for HeartSciences (HSCSW)?

The most recent SEC filing for HeartSciences (HSCSW) was filed on November 19, 2026.